OSR Holdings, Inc. - Common Stock (OSRH)
1.0800
+0.0200 (1.89%)
NASDAQ · Last Trade: Jul 21st, 7:42 PM EDT
Detailed Quote
Previous Close | 1.060 |
---|---|
Open | 1.150 |
Bid | 1.060 |
Ask | 1.080 |
Day's Range | 1.045 - 1.150 |
52 Week Range | 0.9995 - 10.00 |
Volume | 254,537 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 226,826 |
Chart
News & Press Releases
Via Benzinga · July 18, 2025
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · July 18, 2025
Via Benzinga · July 3, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · May 22, 2025
In a market increasingly driven by breakthrough science and resource scarcity, a handful of sub-$2 stocks are making headlines with bold strategies, compelling partnerships, and game-changing data. From immunotherapy innovations to neuromodulation tech, metallic-rich exploration zones and wireless signal innovation, these companies are pushing the envelope—and attracting serious investor attention in the process.
Via AB Newswire · April 3, 2025
Via Benzinga · April 3, 2025
Via Benzinga · April 3, 2025
Via Benzinga · March 27, 2025
Via Benzinga · March 27, 2025
Via Benzinga · March 27, 2025
Health In Tech Inc. (NASDAQ: HIT), OSR Holdings Inc. (NASDAQ: OSRH), Theratechnologies Inc. (NASDAQ: THTX), and Leap Therapeutics Inc. (NASDAQ: LPTX) continue to push boundaries in healthcare through breakthroughs in insurtech, virtual access, immunotherapy, biologics, and precision oncology.
Via AB Newswire · March 26, 2025
Via Benzinga · March 26, 2025
Via Benzinga · March 26, 2025
Via Benzinga · March 26, 2025
Via Benzinga · March 26, 2025
Via Benzinga · March 26, 2025
Via Benzinga · March 19, 2025
Via Benzinga · March 19, 2025
Via Benzinga · March 18, 2025
Via Benzinga · March 13, 2025